Nadofaragene firadenovec

Nadofaragene firadenovec, sold under the brand name Adstiladrin, is a gene therapy used to treat high-risk bladder cancer. It consists of a non-replicating adenoviral vector that delivers the gene for interferon alfa-2b directly into the bladder through a catheter, prompting bladder cells to produce the interferon protein and mount an immune response against tumor cells. It is indicated for adults with high-risk, Bacillus Calmette-Guerin unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. In its pivotal trial, about half of participants achieved a complete response, with some maintaining that response for a year or more. The United States Food and Drug Administration approved it in December 2022. It is developed and marketed by Ferring Pharmaceuticals A/S.